Schizophrenia Drugs Market Regional Analysis

North America is estimated to emerge as the leader in terms of schizophrenia drug demand owing to high awareness regarding mental health and growing prevalence of schizophrenia. Launch of new menta health awareness campaigns, presence of key schizophrenia drug providers, and high investments in R&D of novel schizophrenia treatment therapies and drugs are also contributing to the dominance of this region. Increasing aging population opting for treatment of long-standing schizophrenia and rising number of young adults suffering from schizophrenia are also boosting sales of schizophrenia drugs in North America. Canada and the United States are estimated to be the leading markets for schizophrenia drug companies operating in this region.  

The Asia Pacific region is emerging as a highly opportune market for schizophrenia drug companies in the world. Growing awareness regarding schizophrenia, the launch of new initiatives to improve mental health awareness and rising healthcare expenditure are key factors making this region the fastest-growing market. Japan, Australia, South Korea, and China are forecasted to be the top markets for schizophrenia drug companies looking to make a mark in the Asia Pacific region. Efforts to reduce stigma around mental health issues and the growing integration of mental health with primary care offerings are also creating new business scope for schizophrenia drug providers over the coming years.